Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2004

View Archived Issues

GW receives Qualifying Notice for Sativex in Canada

Positive results from mouse study of universal influenza A vaccine

FDA extends review of cilansetron NDA

Actelion begins global phase IIb/III program for clazosentan

Promics completes study of oral PMX-53 in rheumatoid arthritis

Activity of RAD-001 in hematologic malignancies studied in cells and patients

In vivo effects of bridging therapy with BAY-59-7939 in rats

Dosing begins in phase II obesity study of APD-356

Neurochem grants Centocor rights to Fibrillex

Bristol-Myers Squibb and Somerset sign agreement for Emsam

Access files IND for U.S. clinical studies of AP-5346

OXI-4503 enters U.K. phase I trial in advanced cancer patients

IoGen enters pivotal phase III study for fibrocystic breast disease

Pharmagene updates progress

Disappointing topline results from phase III study of alvimopan

Ortho-McNeil selects Arena compounds for preclinical development

Bristol-Myers Squibb submits muraglitazar NDA

Rolling BLA for abatacept to be completed in early 2005

Approval of the merger of Aventis with and into sanofi-aventis

Advate approved in Europe for children under six with hemophilia A

Bz-423, a novel benzodiazepine, suppresses cell growth in an in vitro psoriasis model

New treatment for Parkinson's disease described in patent literature

Cdk inhibitors in early development at GPC Biotech

TaiGen Biotechnology patent discloses CXCR3 receptor antagonists

Novel agents for treatment of hepatitis C infection described in a patent

Pfizer team reports series of PPAR agonists for dyslipidemia, hypercholesteremia, etc.

5-HT1B receptors are involved in cocaine sensitization

Novel estrogen receptor antagonist for ER-sensitive breast cancer

First clinical data for novel antidepressant published